Skip to content
HowShorted

INTERCEPT PHARMACEUTICALS, INC. short interest in 2021

In 2021, INTERCEPT PHARMACEUTICALS, INC.'s disclosed short interest ran from 21.58% of shares outstanding on 15 Jan 2021 to 28.46% on 31 Dec 2021, a change of +6.88 percentage points. The year's high was 29.10% on 15 Dec 2021 and its low 14.91% on 15 Jul 2021, averaging 22.25% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.99 days on 29 Oct 2021. Full history: INTERCEPT PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for INTERCEPT PHARMACEUTICALS, INC. in 2021

2021 in figures

Start of year
21.58% (15 Jan 2021)
End of year
28.46% (31 Dec 2021)
Change
+6.88 pp
High
29.10% (15 Dec 2021)
Low
14.91% (15 Jul 2021)
Average
22.25%
Highest days to cover
15.99 (29 Oct 2021)
SEC filings marked
8

Every report in 2021

INTERCEPT PHARMACEUTICALS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202121.58%5.90
29 Jan 202121.09%6.18
12 Feb 202118.26%10.35
26 Feb 202119.40%7.2810-K filed, results (8-K)
15 Mar 202121.94%6.51
31 Mar 202122.65%7.73
15 Apr 202122.66%8.62
30 Apr 202119.45%5.41
14 May 202118.85%6.8810-Q filed, results (8-K)
28 May 202118.26%5.34
15 Jun 202117.23%7.12
30 Jun 202115.24%7.96
15 Jul 202114.91%10.85
30 Jul 202115.28%10.2510-Q filed, results (8-K)
13 Aug 202125.60%5.80
31 Aug 202123.20%6.42
15 Sep 202125.59%9.49
30 Sep 202126.88%10.27
15 Oct 202126.19%12.18
29 Oct 202125.49%15.99
15 Nov 202128.33%6.4810-Q filed, results (8-K)
30 Nov 202128.24%12.29
15 Dec 202129.10%8.09
31 Dec 202128.46%9.64

See also: INTERCEPT PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.